Nuclear imaging in Parkinson’s disease- The past, the present, and the future.
Published by Isotopia, 16th May 2022 Published by Isotopia, 16th
Overcoming Lutetium-177 Production and Supply Challenges
Published by Isotopia, 21th April 2022 Published by Isotopia, 21th
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Take home message: Take home message: The vision study is
Vision study – Research on Prostate Cancer
177Lu-PSMA-617 radioligand therapy in mCRPC – VISION phase 3 trial
Lutetium 177 production (Lu177 production)
Carrier Added (CA) and Non-Carrier Added (NCA) The production of
PERSONALIZED NUCLEAR MOLECULAR CANCER THERAPY
For decades, physicians and patients knew three classic treatments for
Prostate cancer
Innovative metastatic prostate cancer treatment with 177-Lu-PSMA. Prostate cancer is the most
